Gongyan Chen
A5109716707- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Gastric Cancer Management and Outcomes
- Immune Cell Function and Interaction
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Hepatocellular Carcinoma Treatment and Prognosis
- Neutropenia and Cancer Infections
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Nutrition and Health in Aging
- Metastasis and carcinoma case studies
- HER2/EGFR in Cancer Research
- Cancer Research and Treatments
- Brain Metastases and Treatment
- Cytokine Signaling Pathways and Interactions
- Cancer Diagnosis and Treatment
- Cancer survivorship and care
- vaccines and immunoinformatics approaches
- Pancreatic and Hepatic Oncology Research
- PI3K/AKT/mTOR signaling in cancer
Harbin Medical University
2015-2025
Third Affiliated Hospital of Harbin Medical University
2015-2025
First Affiliated Hospital of Harbin Medical University
2020-2023
Temple University Health System
2023
Ningxia Meteorological Bureau
2021
Fudan University Shanghai Cancer Center
2015-2021
Shandong Tumor Hospital
2021
Shandong First Medical University
2021
Ruijin Hospital
2021
Weifang People's Hospital
2021
Purpose The phase III BEYOND trial was undertaken to confirm in a Chinese patient population the efficacy seen with first-line bevacizumab plus platinum doublet chemotherapy globally conducted studies. Patients and Methods age ≥ 18 years locally advanced, metastatic, or recurrent advanced nonsquamous non–small-cell lung cancer (NSCLC) were randomly assigned receive carboplatin (area under curve, 6) intravenously paclitaxel (175 mg/m 2 ) (CP) on day 1 of each 3-week cycle, for ≤ six cycles,...
IntroductionSintilimab, an anti–programmed death 1 antibody, plus pemetrexed and platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We conducted randomized, double-blind, 3 study to compare the safety of sintilimab with placebo, both combination such chemotherapy (ClinicalTrials.gov: NCT03607539).MethodsA total 397 patients previously untreated, locally advanced or metastatic without sensitizing EGFR anaplastic lymphoma kinase genomic aberration were...
Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has changed the approach to first-line treatment in patients extensive-stage small lung cancer (SCLC). It remained unknown whether adding a programmed (PD-1) inhibitor provided similar or better benefits SCLC, which would add evidence on efficacy of checkpoint SCLC. Objective To evaluate and adverse event profile PD-1 serplulimab plus compared placebo as Design, Setting, Participants This international,...
Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as first-line treatment for locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC; ClinicalTrials.gov identifier: NCT03849768).Patients at 53 sites China were randomly assigned 1:1 to receive either (110 mg)...
Targeted therapies against non-small-cell lung cancer (NSCLC) harboring HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of pyrotinib in patients with HER2-mutant advanced NSCLC a prospective, multicenter, open-label, single-arm, phase II study.Patients stage IIIB or IV adenocarcinoma who were previously treated platinum-based chemotherapy enrolled to receive at dose 400 mg/d for 21-day cycles. The primary end point was objective response rate per...
Abstract Purpose: Our preclinical work suggests that appropriate angiogenesis inhibition could potentiate PD-1/PD-L1 blockade via alleviating hypoxia, increasing infiltration of CD8+ T cells and reducing recruitment tumor-associated macrophages. We hereby conducted a clinical trial to evaluate this combination in pretreated patients with advanced non–small cell lung cancer (NSCLC). Patients Methods: The study included phase Ib apatinib dose-escalation II expansion cohorts. received at doses...
IntroductionSintilimab plus chemotherapy significantly prolonged progression-free survival (PFS) compared with alone in nonsquamous NSCLC the ORIENT-11 study. Updated overall (OS) and PFS data corresponding biomarker analyses are reported here.MethodsIn this study, a total of 397 patients previously untreated, locally advanced or metastatic were assigned to sintilimab combination treatment (combo) group placebo group. The stratified by programmed death-ligand 1 (PD-L1) expression levels....
In the global KEYNOTE-042 study (Clinicaltrials.gov, NCT02220894), pembrolizumab significantly improved overall survival (OS) vs chemotherapy in patients with previously untreated programmed death ligand 1 (PD-L1)-positive locally advanced/metastatic non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations. We present results from enrolled China or extension (NCT03850444; protocol identical to study). Patients were randomized 1:1 (stratified by ECOG performance status 0 1, squamous...
Abstract Background Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall (OS) compared to alone as first-line treatment in advanced lung squamous cell carcinoma (LUSC) the phase III trial (CameL-sq), which has become an option of standard-of-cares for Chinese patients with LUSC. However, predictive biomarkers remain unknown. Methods Tumor tissue samples at baseline, peripheral blood baseline (pretreatment) after two cycles (on-treatment) were...
7520 Background: The OPTIMAL study demonstrated significant superiority for E versus GC in terms of progression-free survival (PFS), objective response rate, tolerability and quality life (QoL) first-line advanced NSCLC patients with EGFR activating mutations (Act Mut+). Here we report OS data from (ClinicalTrials.gov NCT00874419). Methods: Chemotherapy-naive Chinese Act Mut+, ECOG performance status (PS) 0–2 measurable disease were randomized to (150 mg/day), or GC, stratified by histology,...
IntroductionZL-2306-005 is a randomized, double-blind, multicenter phase 3 study evaluating the efficacy and safety of niraparib, poly(adenosine diphosphate-ribose) polymerase inhibitor, as first-line maintenance therapy in Chinese patients with platinum-responsive, extensive-stage SCLC (ES-SCLC).MethodsPatients complete response (CR) or partial (PR) to standardized, platinum-based chemotherapy were randomized 2:1 receive niraparib placebo (300 mg [baseline body weight ≥ 77 kg, platelet...